No Data
Amgen's weight loss drug has shown impressive results with a 20% reduction in weight, but the side effects are high, causing the stock price to plummet by 12.3% at one point!
Even though the weight-loss drug MariTide from amgen met expectations in terms of efficacy, its high side effects, which did not exceed eli lilly and co's Zepbound, and trial results falling below Wall Street's high expectations, caused amgen's stock price to briefly plummet by over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk, which benefited from the Biden administration's policies at the same time. During a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with approximately 11% of patients withdrawing from the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Benzinga Market Summary: Best Buy And Kohl's Cut Outlook, Biden Admin Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs, PResident-Elect Trump Threatens Tariffs On China, Canada And Mexico
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
(ABBV) - Analyzing AbbVie's Short Interest
Eli Lilly Stock Is Rising Tuesday: What's Going On?